Thalita da Matta de Castro

Thalita da Matta de Castro

Auto-generated profile, based on publicly available information

Thalita da Matta de Castro

Department of Medical Affairs, Clinical Studies, and Post-Registration Surveillance (DEAME), Institute of Technology in Immunobiologicals/Bio-Manguinhos, Fundação Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, Brazil

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2023 in Research and Practice in Thrombosis and Haemostasis
Verified
Journal Article
Open access
DMDaniela Palheiro Mendes-de-Almeida
Daniela Palheiro Mendes-de-Almeida
AVAnna Paula Bise Viegas
Anna Paula Bise Viegas
LJLiliam Cristiana Júlio
Liliam Cristiana Júlio
ABAna Paula Pietrowski Bertuol
Ana Paula Pietrowski Bertuol
EFEder Gatti Fernandes
Eder Gatti Fernandes
MMMaria de Lourdes de Sousa Maia
Maria de Lourdes de Sousa Maia
The emergence of new variants of SARS-CoV-2 has led to the administration of different booster vaccines to mitigate COVID-19. Vaccines with adenoviral vectors have been rarely associated with vaccine-induced immune thrombotic thrombocytopenia (VITT). This study aimed to describe 15 cases of VITT after the third and fourth doses of the COVID-19 vaccine in Brazil. Cases were reported after all kinds of anti-SARS-CoV-2 booster vaccinations between October 17, 2021, and September 4, 2022. Of the 26 suspected cases, 15 cases of VITT were analyzed. Of these, 10 were classified as definite VITT, 2 as probable, 1 as possible, and 2 as unlikely. The estimated frequency of definite, probable, or possible VITT was 0.33 cases per million. Cases were assigned to ChAdOx1 (13 cases), Ad26.COV2.S (1 case), and BNT162b2 (1 case). None of the patients received an adenoviral vaccine as a primary vaccination. The average age of participants was 34 years, and symptoms usually appeared 8 days after vaccination. Headache was the most common symptom, and cerebral veins were the most affected thrombotic site. The overall mortality risk was 53%. Anti-platelet factor 4 enzyme-linked immunosorbent assay serology was positive in 11 out of 15 patients (73.3%), negative in 2 (13.3%), and missing in 2 (13.3%). The study confirms that VITT is linked to the first exposure to adenoviral vector vaccines. Since January 2023, Brazil has recommended preferably COVID-19 messenger RNA vaccines for individuals aged 18 to 39 years. We suggest that, in the current disease scenario, COVID-19 adenovirus vaccines should not be the first choice for individuals aged <50 years who have not received a previous dose of this type of vaccine.

1 January 2021
Verified
Conference Paper
Open access
PDF file
TNTatiana Guimaraes de Noronha
Tatiana Guimaraes de Noronha
DADaniele Aguiar
Daniele Aguiar
TCThalita da Matta de Castro
Thalita da Matta de Castro
RBRicardo Cristiano Brum
Ricardo Cristiano Brum
WSWaleska Dias Schwarcz
Waleska Dias Schwarcz
AHAkira Homma
Akira Homma

19 August 2026 in Advances in Rheumatology
Verified
Journal Article
Open access
PDF file
HTHelena Tupinambá
Helena Tupinambá
LPLeticia Rocha Pereira
Leticia Rocha Pereira
CGCarla Gottgtroy
Carla Gottgtroy
BBBlanca Elena Rios Gomes Bica
Blanca Elena Rios Gomes Bica
IMIngrid Bandeira Moss
Ingrid Bandeira Moss
MMMaria de Lourdes de Sousa Maia
Maria de Lourdes de Sousa Maia
Background: Immune-mediated rheumatic diseases (IMRDs) encompass a wide range of rheumatological conditions that have a substantial impact on morbidity and mortality globally. Due to the diversified nature of IMRD symptoms, timely recognition of these conditions in primary care settings can be challenging. The duration between symptom onset and treatment initiation is a key factor influencing prognosis of IMRD. Therefore, this study aims to evaluate the medical journey of individuals with IMRD from symptom onset to treatment. Methods: Cross-sectional observational study based on the analysis of questionnaire responses from 1,327 patients with IMRDs at two reference centers for rheumatic disease treatment in Rio de Janeiro. Quantitative variables were compared using the Mann-Whitney or Kruskal-Wallis test, while categorical and nominal variables were analyzed using McNemar’s test. Results: The median time until the first rheumatologist consultation after symptom onset was 7 months (0,5-216 months) and the median time to obtain a definitive diagnosis of IMRD was 12 months (0,5-216 months). This period was shorter for individuals with systemic lupus erythematosus (SLE), with a median of 8 months (0.5–216 months), and longer for those with psoriatic arthritis (PsA), with a median of 33 months (2-195 months). Additionally, the median time from symptom onset to specific treatment initiation was also 12 months. It was shown that consulting two or more non-rheumatologists doctors before seeing a rheumatologist significantly delayed the IMRD diagnosis (p-value < 0.001). The diagnosis of IMRD had a negative impact on emotional well-being and occupational capacity on 85.9% ( n = 1,139) of participants’ and 68.1% ( n = 903) indicated that their work was somehow affected in a negative way. Throughout the diagnostic journey, negative feelings predominated in the period in which the diagnosis was not defined, but there was a notable shift after the confirmation of the diagnosis with an increase in positive emotions such as happiness, comfort, and well-being. Conclusions: This study provides valuable information on the challenges faced in the medical journey of patients with IMRDs, from delays in diagnosis to barriers in accessing treatment and the impact on well-being, highlighting the need for multifaceted interventions to improve the management of these complex conditions.